Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Zhejiang Hisoar Pharmaceutical Co., Ltd.

Why is Zhejiang Hisoar Pharmaceutical Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 2.16%

The company has been able to generate a Return on Capital Employed (avg) of 2.16% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of -5.79% and Operating profit at -179.56% over the last 5 years

Negative results in Sep 25

NET PROFIT(Q) At CNY -83.69 MM has Fallen at -162.86%
OPERATING CASH FLOW(Y) Lowest at CNY 60.01 MM
INTEREST(HY) At CNY 12.55 MM has Grown at 6.33%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 38.71%, its profits have risen by 49.7%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Zhejiang Hisoar Pharmaceutical Co., Ltd. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Zhejiang Hisoar Pharmaceutical Co., Ltd.

37.97%

0.55

45.14%

China Shanghai Composite

15.17%

1.02

14.86%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-5.79%

EBIT Growth (5y)

-179.56%

EBIT to Interest (avg)

3.95

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.02

Sales to Capital Employed (avg)

0.29

Tax Ratio

1.03%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

2.16%

ROE (avg)

1.59%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.77

EV to EBIT

-43.24

EV to EBITDA

68.52

EV to Capital Employed

1.78

EV to Sales

5.05

PEG Ratio

Dividend Yield

ROCE (Latest)

-4.12%

ROE (Latest)

-2.54%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

NET PROFIT(HY)

Higher at CNY -81.54 MM

PRE-TAX PROFIT(Q)

At CNY 7.89 MM has Grown at 126.12%

RAW MATERIAL COST(Y)

Fallen by -21.73% (YoY

-18What is not working for the Company

NET PROFIT(Q)

At CNY -83.69 MM has Fallen at -162.86%

OPERATING CASH FLOW(Y)

Lowest at CNY 60.01 MM

INTEREST(HY)

At CNY 12.55 MM has Grown at 6.33%

DEBT-EQUITY RATIO (HY)

Highest at 0.59 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.69 times

Here's what is working for Zhejiang Hisoar Pharmaceutical Co., Ltd.

Pre-Tax Profit

At CNY 7.89 MM has Grown at 126.12%

over average net sales of the previous four periods of CNY -30.19 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Raw Material Cost

Fallen by -21.73% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Zhejiang Hisoar Pharmaceutical Co., Ltd.

Net Profit

At CNY -83.69 MM has Fallen at -162.86%

over average net sales of the previous four periods of CNY -31.84 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Interest

At CNY 12.55 MM has Grown at 6.33%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at 0.59 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Operating Cash Flow

Lowest at CNY 60.01 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Inventory Turnover Ratio

Lowest at 1.69 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Non Operating Income

Highest at CNY 35.81 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income